Clinical Trial Detail

NCT ID NCT03798639
Title Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Hiral Shah
Indications

Merkel cell carcinoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.